Insights

After years of stagnation, the iNTS vaccine pipeline is gaining momentum, with early-stage approaches emerging. Despite high disease burden and rising antimicrobial resistance, particularly in sub-Saharan Africa, no licensed vaccines exist, underscoring a critical gap and need for innovation and clearer pathways to licensure.

The end of clinical failure in Alzheimer’s has unlocked a market of historic proportions. With 140+ therapies in development, clinical success is now just the price of entry. At Shift Health, we believe leadership requires a transition “beyond the molecule” toward an ecosystem-wide strategy focused on four critical pillars.

Alzheimer’s disease represents one of the most urgent and complex challenges facing healthcare systems worldwide. The emergence of disease-modifying therapies, together with advances in digital diagnostic tools and blood-based biomarkers, signals a new era of possibility—one that demands bold action and system-wide readiness.

Ontario’s life sciences sector is a global leader in research and talent—but a critical shortage of seed-stage capital is limiting its ability to commercialize innovation and retain homegrown companies. A new report from Life Sciences Ontario and Shift Health outlines the urgency of this challenge and presents a clear roadmap for change.

Recognizing the potential for CAR T to transform the way we treat some of the most complex conditions, Shift Health assembled a multidisciplinary panel of experts to develop concrete recommendations to prepare Canadian healthcare systems to enhance equitable access to this innovative treatment.

This peer-reviewed paper presents solutions to alleviate health system capacity constraints for retinal care.